UA76731C2 - Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації - Google Patents
Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації Download PDFInfo
- Publication number
- UA76731C2 UA76731C2 UA2003054618A UA200354618A UA76731C2 UA 76731 C2 UA76731 C2 UA 76731C2 UA 2003054618 A UA2003054618 A UA 2003054618A UA 200354618 A UA200354618 A UA 200354618A UA 76731 C2 UA76731 C2 UA 76731C2
- Authority
- UA
- Ukraine
- Prior art keywords
- mma
- virus
- strain
- vaccine
- cells
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract description 83
- 238000000034 method Methods 0.000 title abstract description 29
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 title abstract 2
- 238000002649 immunization Methods 0.000 title description 76
- 230000003053 immunization Effects 0.000 title description 55
- 108090000623 proteins and genes Proteins 0.000 title description 34
- 150000007523 nucleic acids Chemical group 0.000 title description 17
- 102000004169 proteins and genes Human genes 0.000 title description 16
- 108090000765 processed proteins & peptides Proteins 0.000 title description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 title description 6
- 239000008194 pharmaceutical composition Substances 0.000 title description 5
- 238000002360 preparation method Methods 0.000 title description 3
- ZBMRKNMTMPPMMK-UHFFFAOYSA-N 2-amino-4-[hydroxy(methyl)phosphoryl]butanoic acid;azane Chemical compound [NH4+].CP(O)(=O)CCC(N)C([O-])=O ZBMRKNMTMPPMMK-UHFFFAOYSA-N 0.000 title 1
- 238000000338 in vitro Methods 0.000 title 1
- 241000700605 Viruses Species 0.000 abstract description 191
- 230000036039 immunity Effects 0.000 abstract description 49
- 230000028993 immune response Effects 0.000 abstract description 43
- 238000002560 therapeutic procedure Methods 0.000 abstract description 39
- 210000005260 human cell Anatomy 0.000 abstract description 21
- 230000000840 anti-viral effect Effects 0.000 abstract description 19
- 239000003814 drug Substances 0.000 abstract description 14
- 230000001939 inductive effect Effects 0.000 abstract description 8
- 230000002238 attenuated effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 149
- 101800003332 Metamorphosin A Proteins 0.000 description 123
- 241001465754 Metazoa Species 0.000 description 76
- 241000282414 Homo sapiens Species 0.000 description 66
- 208000015181 infectious disease Diseases 0.000 description 64
- 241000700647 Variola virus Species 0.000 description 62
- 238000002255 vaccination Methods 0.000 description 54
- 241000699670 Mus sp. Species 0.000 description 47
- 230000010076 replication Effects 0.000 description 40
- 241000282693 Cercopithecidae Species 0.000 description 36
- 238000011081 inoculation Methods 0.000 description 35
- 108020004414 DNA Proteins 0.000 description 34
- 230000006698 induction Effects 0.000 description 32
- 241000700626 Cowpox virus Species 0.000 description 29
- 241000700618 Vaccinia virus Species 0.000 description 27
- 239000000203 mixture Substances 0.000 description 27
- 238000012360 testing method Methods 0.000 description 27
- 230000004044 response Effects 0.000 description 25
- 230000003321 amplification Effects 0.000 description 22
- 238000003199 nucleic acid amplification method Methods 0.000 description 22
- 101100311270 Arabidopsis thaliana STI gene Proteins 0.000 description 21
- 101100124982 Glycine max HOP1 gene Proteins 0.000 description 21
- 201000003740 cowpox Diseases 0.000 description 18
- 210000000987 immune system Anatomy 0.000 description 18
- 230000001771 impaired effect Effects 0.000 description 18
- 239000002671 adjuvant Substances 0.000 description 15
- 241000282412 Homo Species 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 230000012010 growth Effects 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 230000033458 reproduction Effects 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 231100000518 lethal Toxicity 0.000 description 10
- 230000001665 lethal effect Effects 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 9
- 210000003292 kidney cell Anatomy 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 206010046865 Vaccinia virus infection Diseases 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 210000001672 ovary Anatomy 0.000 description 8
- 230000003362 replicative effect Effects 0.000 description 8
- 208000007089 vaccinia Diseases 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 239000012678 infectious agent Substances 0.000 description 7
- 206010022000 influenza Diseases 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 241000699800 Cricetinae Species 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 6
- 238000011225 antiretroviral therapy Methods 0.000 description 6
- 235000013330 chicken meat Nutrition 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241001430294 unidentified retrovirus Species 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 239000000654 additive Substances 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 206010058874 Viraemia Diseases 0.000 description 4
- 239000003708 ampul Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000003519 mature b lymphocyte Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 241000282560 Macaca mulatta Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000003313 weakening effect Effects 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000798 anti-retroviral effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000008873 bone osteosarcoma Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 230000006054 immunological memory Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000013102 re-test Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000234671 Ananas Species 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010048909 Boredom Diseases 0.000 description 1
- OWNRRUFOJXFKCU-UHFFFAOYSA-N Bromadiolone Chemical compound C=1C=C(C=2C=CC(Br)=CC=2)C=CC=1C(O)CC(C=1C(OC2=CC=CC=C2C=1O)=O)C1=CC=CC=C1 OWNRRUFOJXFKCU-UHFFFAOYSA-N 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 241000867607 Chlorocebus sabaeus Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101150047030 ERO1 gene Proteins 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102100037008 Factor in the germline alpha Human genes 0.000 description 1
- 206010018785 Gingival infections Diseases 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 101000878291 Homo sapiens Factor in the germline alpha Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 101150030986 KAS gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 101800001776 Nuclear inclusion protein B Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 206010073261 Ovarian theca cell tumour Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 241000610446 Schima Species 0.000 description 1
- 206010042135 Stomatitis necrotising Diseases 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000034817 Waterborne disease Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- -1 for example Proteins 0.000 description 1
- 238000005242 forging Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 201000008585 noma Diseases 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000009021 pre-vaccination Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008593 response to virus Effects 0.000 description 1
- 238000012770 revaccination Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 208000001644 thecoma Diseases 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200001764 | 2000-11-23 | ||
| PCT/EP2001/013628 WO2002042480A2 (en) | 2000-11-23 | 2001-11-22 | Modified vaccinia ankara virus variant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA76731C2 true UA76731C2 (uk) | 2006-09-15 |
Family
ID=8159864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2003054618A UA76731C2 (uk) | 2000-11-23 | 2001-11-22 | Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації |
Country Status (30)
| Country | Link |
|---|---|
| US (11) | US6761893B2 (no) |
| EP (4) | EP2204452A1 (no) |
| JP (1) | JP4421188B2 (no) |
| KR (3) | KR100910297B1 (no) |
| CN (2) | CN100537773C (no) |
| AT (1) | ATE314483T2 (no) |
| AU (2) | AU2002231639B2 (no) |
| BE (1) | BE2013C065I2 (no) |
| BR (1) | BRPI0115533B8 (no) |
| CA (1) | CA2421151C (no) |
| CY (2) | CY1105594T1 (no) |
| CZ (1) | CZ295808B6 (no) |
| DE (2) | DE20122302U1 (no) |
| DK (1) | DK1335987T4 (no) |
| EE (1) | EE05680B1 (no) |
| ES (1) | ES2256323T5 (no) |
| FR (1) | FR13C0070I2 (no) |
| HK (1) | HK1059453A1 (no) |
| HU (2) | HU230198B1 (no) |
| IL (2) | IL154712A0 (no) |
| LU (1) | LU92311I2 (no) |
| MX (1) | MXPA03002513A (no) |
| NO (1) | NO337867B1 (no) |
| NZ (1) | NZ524661A (no) |
| PL (1) | PL212047B1 (no) |
| PT (1) | PT1335987E (no) |
| RU (1) | RU2290438C2 (no) |
| SI (1) | SI1335987T2 (no) |
| UA (1) | UA76731C2 (no) |
| WO (1) | WO2002042480A2 (no) |
Families Citing this family (151)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7097842B2 (en) | 2000-11-23 | 2006-08-29 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US7628980B2 (en) | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US7445924B2 (en) | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
| EP2204452A1 (en) | 2000-11-23 | 2010-07-07 | Bavarian Nordic A/S | Modified Vaccinia Ankara Virus variant |
| UA82466C2 (uk) * | 2001-07-18 | 2008-04-25 | Бавариан Нордика А/С | Спосіб посилення ампліфікації хордопоксвірусу |
| CN101397574A (zh) * | 2001-12-04 | 2009-04-01 | 巴法里安诺迪克有限公司 | 黄病毒ns1亚单位疫苗 |
| NZ547776A (en) † | 2002-04-19 | 2009-08-28 | Bavarian Nordic As | Modified vaccinia virus ankara for protecting an animal against an antigen or self-protein |
| US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| CN1289682C (zh) * | 2002-05-16 | 2006-12-13 | 巴法里安诺迪克有限公司 | 通过使用牛痘ati启动子表达改良的安卡拉痘苗病毒中的基因 |
| ES2256776T3 (es) | 2002-05-16 | 2006-07-16 | Bavarian Nordic A/S | Regiones intergenicas como sitios de insercion en el genoma del virus vaccinia ankara modificado (mva). |
| JP2005537793A (ja) | 2002-09-05 | 2005-12-15 | バヴァリアン・ノルディック・アクティーゼルスカブ | 無血清条件下で初代細胞を培養する方法及びウイルスを増幅させる方法 |
| DE602004009743T2 (de) * | 2003-11-24 | 2008-08-28 | Bavarian Nordic A/S | Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara |
| WO2005120579A1 (ja) * | 2004-06-14 | 2005-12-22 | Ishihara Sangyo Kaisha, Ltd. | 膜融合活性のある不活性化ウイルスエンベロープの凍結乾燥組成物 |
| CN1295339C (zh) * | 2005-01-11 | 2007-01-17 | 武汉大学 | 减毒痘苗病毒天坛株载体及制备方法和应用 |
| LT1855720T (lt) * | 2005-02-23 | 2017-01-10 | Bavarian Nordic A/S | Modifikuoto raupų viruso panaudojimas greitam imuniteto sužadinimui prieš raupų virusą arba kitus infekcinius agentus |
| US20090269365A1 (en) * | 2005-04-20 | 2009-10-29 | University Of Washington | Immunogenic vaccinia peptides and methods of using same |
| KR100717279B1 (ko) * | 2005-08-08 | 2007-05-15 | 삼성전자주식회사 | 마스크롬 소자 및 그 형성 방법 |
| US7913477B2 (en) * | 2006-01-27 | 2011-03-29 | William Anthony Harper | Insert registration in packets |
| EP1826264A1 (en) * | 2006-02-24 | 2007-08-29 | Deutsches Primatenzentrum GmbH | Primate model for orthopox virus infections |
| EP1835031A1 (en) | 2006-03-14 | 2007-09-19 | Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe | Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans |
| MX348525B (es) * | 2006-06-20 | 2017-06-16 | Transgene Sa | Proceso para producir poxvirus y composiciones de poxvirus. |
| CN101472610A (zh) | 2006-06-20 | 2009-07-01 | 特朗斯吉有限公司 | 重组病毒疫苗 |
| WO2008028665A1 (en) * | 2006-09-08 | 2008-03-13 | Bavarian Nordic A/S | Phenotypic and genotypic differences of mva strains |
| US7807146B2 (en) * | 2006-10-06 | 2010-10-05 | Bn Immunotherapeutics, Inc. | Methods for treating cancer with a recombinant MVA expressing HER-2 |
| US8268327B2 (en) | 2007-04-27 | 2012-09-18 | Bavarian Nordic A/S | Immediate protection against pathogens via MVA |
| US8003364B2 (en) * | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia viruses using hydrophobic interaction chromatography |
| EP2152862A1 (en) | 2007-05-14 | 2010-02-17 | Bavarian Nordic A/S | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
| KR20160065985A (ko) * | 2007-10-18 | 2016-06-09 | 버베리안 노딕 에이/에스 | 전립선 암 치료를 위한 ｍｖａ의 용도 |
| KR100970449B1 (ko) * | 2007-12-21 | 2010-07-16 | (주)이지아이 | 안전성을 갖는 어린이 놀이터용 고무 바닥재 및 설치방법 |
| EP2303322A1 (en) * | 2008-06-20 | 2011-04-06 | Bavarian Nordic A/S | Recombinant modified vaccinia virus measles vaccine |
| WO2010084100A1 (en) | 2009-01-20 | 2010-07-29 | Transgene Sa | Soluble icam-1 as biomarker for prediction of therapeutic response |
| US8394385B2 (en) * | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| US8613936B2 (en) | 2009-03-13 | 2013-12-24 | Bavarian Nordic A/S | Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements |
| KR20110138354A (ko) | 2009-03-24 | 2011-12-27 | 트랜스진 에스.에이. | 환자를 모니터링하기 위한 바이오마커 |
| PL2419728T3 (pl) | 2009-04-17 | 2014-05-30 | Transgene Sa | Biomarker do monitorowania pacjentów |
| DK2452194T3 (en) | 2009-07-10 | 2015-11-30 | Transgene Sa | Biomarker PATIENT SELECTION AND RELATED PRACTICES |
| MX2012002531A (es) * | 2009-10-08 | 2012-04-11 | Bavarian Nordic As | Generacion de una respuesta amplia de celulas t en humanos contra el virus de inmunodeficiencia humana (vih). |
| CA2781397A1 (en) * | 2009-11-20 | 2011-05-26 | Inviragen, Inc. | Compositions, methods and uses for poxvirus elements in vaccine constructs |
| US8859257B2 (en) | 2010-01-28 | 2014-10-14 | Bavarian Nordic A/S | Vaccinia virus mutants containing the major genomic deletions of MVA |
| AU2011230619C1 (en) | 2010-03-25 | 2016-06-23 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
| EP2596099B1 (en) | 2010-07-20 | 2019-11-27 | Bavarian Nordic A/S | Method for harvesting expression products |
| WO2012018856A2 (en) * | 2010-08-02 | 2012-02-09 | Virxsys Corporation | Hiv vaccine therapy with concomitant antiviral monotherapy |
| AU2011316164B2 (en) * | 2010-10-15 | 2016-01-14 | Bavarian Nordic A/S | Recombinant modified vaccinia virus Ankara (MVA) influenza vaccine |
| DK2691530T3 (en) | 2011-06-10 | 2018-05-22 | Univ Oregon Health & Science | CMV GLYCOPROTEIN AND RECOMBINANT VECTORS |
| JP6243333B2 (ja) * | 2011-08-05 | 2017-12-06 | シラジェン バイオセラピューティクス インコーポレイテッド | ワクシニアウィルスの生成のための方法および組成物 |
| EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
| EP2788021B1 (en) | 2011-12-09 | 2017-01-18 | Bavarian Nordic A/S | Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c |
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| EP2864487B1 (en) | 2012-06-22 | 2018-12-05 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
| EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
| WO2014009433A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterium resuscitation promoting factor for use as adjuvant |
| EA029492B1 (ru) | 2012-07-10 | 2018-04-30 | Трансген Са | Вакцина на основе микобактериальных антигенов |
| MX362511B (es) | 2012-08-01 | 2019-01-22 | Bavarian Nordic As | Vacuna del virus vaccinia ankara modificado (mva) recombinante para virus sincicial respiratorio (vsr). |
| EP2892549A1 (en) * | 2012-09-04 | 2015-07-15 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
| WO2014043535A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
| EP2908851A1 (en) | 2012-10-19 | 2015-08-26 | Bavarian Nordic Inc. | Methods and compositions for the treatment of cancer |
| SG10201704657WA (en) | 2012-10-28 | 2017-07-28 | Bavarian Nordic As | Pr13.5 promoter for robust t-cell and antibody responses |
| KR102269491B1 (ko) * | 2013-03-15 | 2021-06-25 | 버베리안 노딕 에이/에스 | 단회 고용량의 mva가 신생아 및 영아에서 보호 면역 반응을 유도 |
| EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
| EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| AU2014340201B2 (en) | 2013-10-23 | 2019-02-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use |
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| NZ759538A (en) | 2013-11-28 | 2022-10-28 | Bavarian Nordic As | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors |
| WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| WO2015095811A2 (en) | 2013-12-20 | 2015-06-25 | The Board Institute Inc. | Combination therapy with neoantigen vaccine |
| CA2936131A1 (en) | 2014-01-09 | 2015-07-16 | Transgene Sa | Fusion of heterooligomeric mycobacterial antigens |
| IL248511B (en) | 2014-05-13 | 2022-07-01 | Bavarian Nordic As | Combined therapy for the treatment of cancer with a focovirus expressing the antigen and a monoclonal antibody against tim-3 |
| CA2951430A1 (en) | 2014-06-13 | 2015-12-17 | Glaxosmithkline Biologicals Sa | Immunogenic combinations |
| CN107106673A (zh) | 2014-09-03 | 2017-08-29 | 巴法里安诺迪克有限公司 | 用于增强免疫应答的方法和组合物 |
| HUE048318T2 (hu) | 2014-09-03 | 2020-07-28 | Bavarian Nordic As | Módszerek és készítmények a filovírus fertõzés elleni védõ immunitás kialakítására |
| SG11201702110RA (en) | 2014-09-26 | 2017-04-27 | Beth Israel Deaconess Medical Ct Inc | Methods and compositions for inducing protective immunity against human immunodeficiency virus infection |
| KR101645642B1 (ko) | 2014-10-16 | 2016-08-11 | 대한민국 | Kvac１０３ 유래의 재조합 백시니아 바이러스 |
| KR101623498B1 (ko) | 2014-10-16 | 2016-05-24 | 대한민국 | 약독화 백시니아 바이러스주 kvac１０３ |
| SG11201702997YA (en) | 2014-11-04 | 2017-05-30 | Janssen Vaccines & Prevention Bv | Therapeutic hpv16 vaccines |
| US10993997B2 (en) | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
| US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
| AU2016229408A1 (en) | 2015-02-25 | 2017-09-14 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| CN107847534B (zh) | 2015-04-17 | 2022-10-04 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
| BR112017024797A2 (pt) | 2015-05-20 | 2018-08-07 | The Broad Institute Inc. | neoantígenos partilhados |
| TWI750122B (zh) | 2015-06-09 | 2021-12-21 | 美商博德研究所有限公司 | 用於贅瘤疫苗之調配物及其製備方法 |
| MX2017016273A (es) * | 2015-06-15 | 2018-04-20 | Bavarian Nordic As | Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante. |
| US9925258B2 (en) | 2015-10-02 | 2018-03-27 | International Aids Vaccine Initiative | Replication-competent VSV-HIV Env vaccines |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| CN106591361A (zh) * | 2015-10-20 | 2017-04-26 | 钱文斌 | 一种重组痘溶瘤病毒及其构建方法和应用 |
| BR112018011122A2 (pt) | 2015-12-15 | 2018-11-21 | Janssen Vaccines & Prevention B.V. | antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos |
| ES2921605T3 (es) | 2016-01-29 | 2022-08-30 | Bavarian Nordic As | Vacuna contra el virus de la encefalitis equina basada en el virus de la variolovacuna modificado Ankara (VMA) recombinante |
| BR112018016948A2 (pt) | 2016-02-25 | 2019-01-08 | Memorial Sloan Kettering Cancer Center | mva recombinante ou mva¿e3l que expressa flt3l humano e uso do mesmo como agente imunoterapêutico contra tumores sólidos |
| MX2018010204A (es) | 2016-02-25 | 2019-05-06 | Memorial Sloan Kettering Cancer Center | Virus de la vaccinia atenuada competentes para replicacion con la supresion de timidina quinasa con y sin la expresion del flt3l o gm-csf humanos para inmunoterapia del cancer. |
| JP7250520B2 (ja) | 2016-04-13 | 2023-04-03 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 組換えアルテリウイルスレプリコン系およびその使用 |
| WO2017184590A1 (en) | 2016-04-18 | 2017-10-26 | The Broad Institute Inc. | Improved hla epitope prediction |
| WO2017192418A1 (en) | 2016-05-02 | 2017-11-09 | Janssen Vaccine & Prevention B.V. | Therapeutic hpv vaccine combinations |
| EA201892735A1 (ru) | 2016-06-16 | 2019-05-31 | Янссен Вэксинс Энд Превеншн Б.В. | Состав вакцины против hiv |
| US10925956B2 (en) | 2016-07-15 | 2021-02-23 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
| US10307477B2 (en) | 2016-09-02 | 2019-06-04 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
| MX2019002938A (es) | 2016-09-15 | 2019-10-15 | Janssen Vaccines & Prevention Bv | Mutaciones estebilizantes de trimeros de proteinas de la envoltura del vih. |
| JP7062003B2 (ja) | 2016-09-28 | 2022-05-02 | バヴァリアン・ノルディック・アクティーゼルスカブ | ポックスウイルス内における導入遺伝子の安定性を向上させるための組成物及び方法 |
| CA3040264A1 (en) | 2016-10-17 | 2018-04-26 | Synthetic Genomics, Inc. | Recombinant virus replicon systems and uses thereof |
| AU2017355564B2 (en) | 2016-11-07 | 2022-04-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Development of agonist epitopes of the human papillomavirus |
| KR102655641B1 (ko) | 2016-12-05 | 2024-04-05 | 얀센 파마슈티칼즈, 인코포레이티드 | 유전자 발현을 향상시키기 위한 조성물 및 방법 |
| WO2018140391A1 (en) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| WO2018185732A1 (en) | 2017-04-06 | 2018-10-11 | Janssen Vaccines & Prevention B.V. | Mva-bn and ad26.zebov or ad26.filo prime-boost regimen |
| WO2018209315A1 (en) | 2017-05-12 | 2018-11-15 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| EP3624845A1 (en) | 2017-05-15 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| AU2018269319A1 (en) | 2017-05-15 | 2019-11-07 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| WO2018229711A1 (en) | 2017-06-15 | 2018-12-20 | Janssen Vaccines & Prevention B.V. | Poxvirus vectors encoding hiv antigens, and methods of use thereof |
| AU2018304502B2 (en) | 2017-07-19 | 2022-03-31 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing HIV envelope protein mutations |
| US20190022212A1 (en) | 2017-07-21 | 2019-01-24 | Beth Israel Deaconess Medical Center, Inc. | Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human |
| EP3691675A1 (en) | 2017-08-24 | 2020-08-12 | Bavarian Nordic A/S | Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an antibody |
| WO2019055888A1 (en) | 2017-09-18 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | METHODS OF INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDER ANTIRETROVIRAL TREATMENT |
| EP3727446A1 (en) | 2017-12-19 | 2020-10-28 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against hepatitis b virus (hbv) |
| EA202091516A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv) |
| US11389531B2 (en) | 2017-12-19 | 2022-07-19 | Janssen Sciences Ireland Unlimited Company | Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines |
| US11021692B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Hepatitis B virus (HBV) vaccines and uses thereof |
| JP2021507712A (ja) | 2017-12-20 | 2021-02-25 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | エプスタインバールウイルス抗原構築物 |
| US11083786B2 (en) | 2018-01-19 | 2021-08-10 | Janssen Pharmaceuticals, Inc. | Induce and enhance immune responses using recombinant replicon systems |
| WO2020014658A1 (en) * | 2018-07-13 | 2020-01-16 | University Of Georgia Research Foundation | Broadly reactive immunogens of dengue virus, compositions, and methods of use thereof |
| JP7437385B2 (ja) | 2018-09-06 | 2024-02-22 | バヴァリアン・ノルディック・アクティーゼルスカブ | 保管が改善されたポックスウイルス組成物 |
| US20210382068A1 (en) | 2018-10-02 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
| US20240269254A1 (en) | 2018-10-05 | 2024-08-15 | Bavarian Nordic A/S | Combination Therapy for Treating Cancer with an Intravenous Administration of a Recombinant MVA and an Immune Checkpoint Antagonist or Agonist |
| WO2020102404A1 (en) | 2018-11-14 | 2020-05-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tp5, a peptide inhibitor of aberrant and hyperactive cdk5/p25 as treatment for cancer |
| MX2021005560A (es) | 2018-11-20 | 2021-06-23 | Bavarian Nordic As | Terapia para el tratamiento del cancer con administracion intratumoral y/o intravenosa de un virus vaccinia ankara (mva) recombinante que codifica ligando 4-1bbl (cd137l) y/o ligando del cumulo o grupo de diferenciacion 40 (cd40l). |
| WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| CA3126462A1 (en) | 2019-01-10 | 2020-07-16 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2020237052A1 (en) | 2019-05-22 | 2020-11-26 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
| US20220305120A1 (en) | 2019-06-11 | 2022-09-29 | Glaxosmithkline Biologicals Sa | Mucosal vaccine formulations |
| BR112022009421A2 (pt) | 2019-11-14 | 2022-10-25 | Aelix Therapeutics S L | Regimes de dosagem para vacinas |
| JOP20220116A1 (ar) | 2019-11-18 | 2023-01-30 | Janssen Biotech Inc | اللقاحات المستندة إلى الطافر calr وjak2 واستخداماتها |
| EP4061406A1 (en) | 2019-11-20 | 2022-09-28 | Bavarian Nordic A/S | Recombinant mva viruses for intratumoral and/or intravenous administration for treating cancer |
| CA3159666A1 (en) | 2019-11-20 | 2021-05-27 | Bavarian Nordic A/S | Medical uses of 4-1bbl adjuvanted recombinant modified vaccinia virus ankara (mva) |
| WO2021150713A2 (en) | 2020-01-21 | 2021-07-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human immunogenic epitopes of h, k, and e human endogenous retroviruses (hervs) |
| US20230287067A1 (en) | 2020-01-21 | 2023-09-14 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Human immunogenic epitopes of hemo and hhla2 human endogenous retroviruses (hervs) |
| IL296250A (en) | 2020-03-12 | 2022-11-01 | Bavarian Nordic As | The compounds that improve the stability of the smallpox virus |
| AU2021290177A1 (en) | 2020-06-10 | 2023-01-19 | Bavarian Nordic A/S | A recombinant Modified Vaccinia Virus Ankara (MVA) vaccine against coronavirus disease |
| EP3928789A1 (en) | 2020-06-24 | 2021-12-29 | Consejo Superior de Investigaciones Científicas (CSIC) | Mva-based vaccine against covid-19 expressing sars-cov-2 antigens |
| WO2021260065A1 (en) | 2020-06-24 | 2021-12-30 | Consejo Superior De Investigaciones Científicas (Csic) | Mva-based vaccine against covid-19 expressing sars-cov-2 antigens |
| TW202216190A (zh) | 2020-07-08 | 2022-05-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 抗hbv之rna複製子疫苗 |
| US20220118081A1 (en) | 2020-10-20 | 2022-04-21 | Janssen Vaccines & Prevention B.V. | HIV vaccine regimens |
| EP4358999A1 (en) | 2021-06-23 | 2024-05-01 | Consejo Superior De Investigaciones Científicas | Mva-based vaccine expressing a prefusion-stabilized sars-cov-2 s protein |
| EP4108257A1 (en) | 2021-06-23 | 2022-12-28 | Consejo Superior De Investigaciones Científicas | Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein |
| EP4396333A1 (en) | 2021-09-03 | 2024-07-10 | Bavarian Nordic A/S | Utilization of micro-rna for downregulation of cytotoxic transgene expression by modified vaccinia virus ankara (mva) |
| AU2022422563A1 (en) | 2021-12-23 | 2024-07-04 | Bavarian Nordic A/S | Therapy for modulating immune response with recombinant mva encoding il-12 |
| WO2023118508A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
| WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
| WO2024003238A1 (en) | 2022-06-29 | 2024-01-04 | Bavarian Nordic A/S | Epstein-barr-virus vaccine |
| WO2024003239A1 (en) | 2022-06-29 | 2024-01-04 | Bavarian Nordic A/S | RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN |
| WO2024003346A1 (en) | 2022-06-30 | 2024-01-04 | Bavarian Nordic A/S | Mammalian cell line for the production of modified vaccinia virus ankara (mva) |
| WO2024015892A1 (en) | 2022-07-13 | 2024-01-18 | The Broad Institute, Inc. | Hla-ii immunopeptidome methods and systems for antigen discovery |
| EP4316514A1 (en) | 2022-08-03 | 2024-02-07 | Consejo Superior de Investigaciones Científicas (CSIC) | Mva-based vectors and their use as vaccine against sars-cov-2 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4072565A (en) * | 1974-11-04 | 1978-02-07 | The Dow Chemical Company | Production of viruses in tissue culture without use of serum |
| US3914408A (en) * | 1973-10-12 | 1975-10-21 | Univ Nebraska | Vaccine for neonatal calf diarrhea |
| DE2714665A1 (de) * | 1977-04-01 | 1978-10-05 | Mayr Anton | Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung |
| US5338683A (en) * | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US5155020A (en) * | 1989-03-08 | 1992-10-13 | Health Research Inc. | Recombinant poxvirus host range selection system |
| GB8322414D0 (en) * | 1983-08-19 | 1983-09-21 | Szelke M | Renin inhibitors |
| FR2603040B1 (fr) | 1986-08-22 | 1990-01-26 | Transgene Sa | Proteine, sequence d'adn, poxvirus, cellules et leur procede de culture, ainsi que les compositions pharmaceutiques les contenant, utiles dans la prevention de la schistosomose |
| AU613583B2 (en) | 1986-08-22 | 1991-08-08 | Transgene S.A. | Proteins and the method for preparing them, DNA sequences, antibodies and their application, poxviruses, transformed or infected cells, pharmaceutical compositions which are useful in the prevention of schistosomiasis and application by way of an agent possessing glutathione s-transferase activity |
| DE3743298A1 (de) | 1987-12-19 | 1989-06-29 | Wilkinson Sword Gmbh | Rasierapparat und verfahren zur herstellung einer flaeche geringen reibungswiderstands an einem rasierapparat |
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| US6248333B1 (en) * | 1990-04-04 | 2001-06-19 | Health Research Inc. | Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD) |
| WO1992005246A1 (en) | 1990-09-25 | 1992-04-02 | Smithkline Beecham Corporation | Medium for culture of mammalian cells |
| US5843456A (en) * | 1991-03-07 | 1998-12-01 | Virogenetics Corporation | Alvac poxvirus-rabies compositions and combination compositions and uses |
| WO1992015672A1 (en) * | 1991-03-07 | 1992-09-17 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US5403582A (en) | 1993-01-21 | 1995-04-04 | Nippon Zeon Co., Ltd. | Vaccine comprising fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus |
| US5405772A (en) | 1993-06-18 | 1995-04-11 | Amgen Inc. | Medium for long-term proliferation and development of cells |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| US5490794A (en) * | 1993-11-05 | 1996-02-13 | Sumitomo Wiring Systems, Ltd. | Branch joint box |
| US6190655B1 (en) | 1993-12-03 | 2001-02-20 | Immunex Corporation | Methods of using Flt-3 ligand for exogenous gene transfer |
| DE4405841C1 (de) * | 1994-02-23 | 1995-01-05 | Mayr Anton Prof Dr Med Vet Dr | Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO1995030018A2 (en) * | 1994-04-29 | 1995-11-09 | Immuno Aktiengesellschaft | Recombinant poxviruses with foreign polynucleotides in essential regions |
| JPH10506004A (ja) * | 1994-07-27 | 1998-06-16 | ザ カウンシル オブ ザ クィーンズランド インスティテュート オブ メディカル リサーチ | ポリエピトープワクチン |
| US5676950A (en) * | 1994-10-28 | 1997-10-14 | University Of Florida | Enterically administered recombinant poxvirus vaccines |
| US5753489A (en) | 1994-11-10 | 1998-05-19 | Immuno Ag | Method for producing viruses and vaccines in serum-free culture |
| US5756341A (en) | 1994-11-10 | 1998-05-26 | Immuno Ag | Method for controlling the infectivity of viruses |
| US5566011A (en) * | 1994-12-08 | 1996-10-15 | Luncent Technologies Inc. | Antiflector black matrix having successively a chromium oxide layer, a molybdenum layer and a second chromium oxide layer |
| UA68327C2 (en) † | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| EA002020B1 (ru) | 1996-02-21 | 2001-12-24 | Джулианна Лисцивич | Способ генерации противовирусного иммунного ответа у человека или животного |
| AU3813597A (en) | 1996-07-26 | 1998-02-20 | University Of Manitoba | Serum-free medium for growth of anchorage-dependant mammalian cells |
| WO1998013500A2 (en) † | 1996-09-24 | 1998-04-02 | Bavarian Nordic Research Institute A/S | Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines |
| WO1998017283A1 (en) | 1996-10-25 | 1998-04-30 | The Wistar Institute Of Anatomy & Biology | Method of vaccinating infants against infections |
| US6204250B1 (en) * | 1996-11-22 | 2001-03-20 | The Mount Sinai Medical Center Of The City Of New York | Immunization of infants |
| US20030138454A1 (en) * | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
| GB0023203D0 (en) | 2000-09-21 | 2000-11-01 | Isis Innovation | Vaccination method |
| GB9711957D0 (en) * | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| DE19729279A1 (de) † | 1997-07-09 | 1999-01-14 | Peter Hildebrandt | Urologisches Implantat, insbesondere Gefäßwandstütze für den Urinaltrakt |
| WO1999007869A1 (en) * | 1997-08-05 | 1999-02-18 | University Of Florida | Live recombinant vaccine comprising inefficiently or non-replicating virus |
| US6667176B1 (en) * | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
| WO2000028016A1 (en) | 1998-11-10 | 2000-05-18 | University Of Rochester | T cells specific for target antigens and methods and vaccines based thereon |
| GB2347932B (en) | 1998-11-18 | 2003-05-07 | Oxford Biomedica Ltd | Vectors for the delivery of 5T4 antigen |
| GB2370572B (en) | 1998-11-18 | 2003-05-07 | Oxford Biomedica Ltd | Use of a professional antigen presenting cell |
| US6173813B1 (en) | 1998-12-23 | 2001-01-16 | Otis Elevator Company | Electronic control for an elevator braking system |
| US6497883B1 (en) | 1999-06-10 | 2002-12-24 | Merial | Porcine circovirus recombinant poxvirus vaccine |
| WO2001092470A2 (en) * | 2000-03-02 | 2001-12-06 | Emory University | Dna expression vectors and methods of use |
| IL150736A0 (en) | 2000-03-14 | 2003-02-12 | Mayr Anton | Altered strain of the modified vaccinia virus ankara (mva) |
| KR100341030B1 (ko) | 2000-03-16 | 2002-06-20 | 유태욱 | 캡션 데이터와 음성 데이터의 재생방법 및 이를 이용한 디스플레이장치 |
| CA2409874A1 (en) | 2000-05-24 | 2001-11-29 | Merial | Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine |
| MXPA03000279A (es) * | 2000-07-11 | 2004-04-05 | Bayer Ag | Uso de cepas del parapoxvirus ovis para la fabricacion de medicamentos antivirales y medicamentos contra el cancer. |
| US6733993B2 (en) * | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
| US7628980B2 (en) * | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US7097842B2 (en) * | 2000-11-23 | 2006-08-29 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| EP2204452A1 (en) * | 2000-11-23 | 2010-07-07 | Bavarian Nordic A/S | Modified Vaccinia Ankara Virus variant |
| US7445924B2 (en) * | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
| UA82466C2 (uk) * | 2001-07-18 | 2008-04-25 | Бавариан Нордика А/С | Спосіб посилення ампліфікації хордопоксвірусу |
| CN101397574A (zh) * | 2001-12-04 | 2009-04-01 | 巴法里安诺迪克有限公司 | 黄病毒ns1亚单位疫苗 |
| WO2003054175A1 (en) | 2001-12-20 | 2003-07-03 | Bavarian Nordic A/S | Method for the recovery and purification of poxviruses from infected cells |
| US7025970B2 (en) | 2002-03-15 | 2006-04-11 | Baxter International Inc. | Modified poxviruses, including modified smallpox virus vaccine based on recombinant drug-sensitive vaccinia virus, and new selection methods |
| NZ547776A (en) * | 2002-04-19 | 2009-08-28 | Bavarian Nordic As | Modified vaccinia virus ankara for protecting an animal against an antigen or self-protein |
| CN1289682C (zh) * | 2002-05-16 | 2006-12-13 | 巴法里安诺迪克有限公司 | 通过使用牛痘ati启动子表达改良的安卡拉痘苗病毒中的基因 |
| ES2256776T3 (es) * | 2002-05-16 | 2006-07-16 | Bavarian Nordic A/S | Regiones intergenicas como sitios de insercion en el genoma del virus vaccinia ankara modificado (mva). |
| JP2005537793A (ja) * | 2002-09-05 | 2005-12-15 | バヴァリアン・ノルディック・アクティーゼルスカブ | 無血清条件下で初代細胞を培養する方法及びウイルスを増幅させる方法 |
| ATE365220T1 (de) * | 2002-11-25 | 2007-07-15 | Bavarian Nordic As | Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus |
| US6976752B2 (en) * | 2003-10-28 | 2005-12-20 | Lexmark International, Inc. | Ink jet printer with resistance compensation circuit |
| DE602004009743T2 (de) * | 2003-11-24 | 2008-08-28 | Bavarian Nordic A/S | Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara |
| EP1586330A1 (en) * | 2004-04-16 | 2005-10-19 | Georg-August-Universität Göttingen | Vaccination against malignant melanoma |
| WO2006044716A2 (en) * | 2004-10-15 | 2006-04-27 | Washington University In St.Louis | CELL PERMEABLE NANOCONJUGATES OF SHELL-CROSSLINKED KNEDEL (SCK) AND PEPTIDE NUCLEIC ACIDS ('PNAs') WITH UNIQUELY EXPRESSED OR OVER-EXPRESSED mRNA TARGETING SEQUENCES FOR EARLY DIAGNOSIS AND THERAPY OF CANCER |
| EP1835031A1 (en) | 2006-03-14 | 2007-09-19 | Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe | Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans |
| US7807146B2 (en) * | 2006-10-06 | 2010-10-05 | Bn Immunotherapeutics, Inc. | Methods for treating cancer with a recombinant MVA expressing HER-2 |
| EP1925318A1 (en) | 2006-11-20 | 2008-05-28 | Paul-Ehrlich-Institut | Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu |
| US8268327B2 (en) * | 2007-04-27 | 2012-09-18 | Bavarian Nordic A/S | Immediate protection against pathogens via MVA |
| KR20160065985A (ko) * | 2007-10-18 | 2016-06-09 | 버베리안 노딕 에이/에스 | 전립선 암 치료를 위한 ｍｖａ의 용도 |
-
2001
- 2001-11-22 EP EP10158053A patent/EP2204452A1/en not_active Withdrawn
- 2001-11-22 BR BRPI0115533A patent/BRPI0115533B8/pt not_active IP Right Cessation
- 2001-11-22 WO PCT/EP2001/013628 patent/WO2002042480A2/en active Application Filing
- 2001-11-22 CN CNB018194109A patent/CN100537773C/zh not_active Expired - Lifetime
- 2001-11-22 PT PT01991753T patent/PT1335987E/pt unknown
- 2001-11-22 AT AT01991753T patent/ATE314483T2/de active
- 2001-11-22 CA CA2421151A patent/CA2421151C/en not_active Expired - Lifetime
- 2001-11-22 AU AU2002231639A patent/AU2002231639B2/en not_active Expired
- 2001-11-22 KR KR1020087007423A patent/KR100910297B1/ko active IP Right Grant
- 2001-11-22 JP JP2002545184A patent/JP4421188B2/ja not_active Expired - Lifetime
- 2001-11-22 EP EP10158051A patent/EP2202315A1/en not_active Withdrawn
- 2001-11-22 EE EEP200300173A patent/EE05680B1/xx unknown
- 2001-11-22 ES ES01991753.3T patent/ES2256323T5/es not_active Expired - Lifetime
- 2001-11-22 CZ CZ20031366A patent/CZ295808B6/cs not_active IP Right Cessation
- 2001-11-22 PL PL361459A patent/PL212047B1/pl unknown
- 2001-11-22 DE DE20122302U patent/DE20122302U1/de not_active Expired - Lifetime
- 2001-11-22 AU AU3163902A patent/AU3163902A/xx active Pending
- 2001-11-22 DE DE60116371.0T patent/DE60116371T3/de not_active Expired - Lifetime
- 2001-11-22 EP EP05017694A patent/EP1598425A1/en not_active Withdrawn
- 2001-11-22 MX MXPA03002513A patent/MXPA03002513A/es active IP Right Grant
- 2001-11-22 EP EP01991753.3A patent/EP1335987B2/en not_active Expired - Lifetime
- 2001-11-22 HU HU0400685A patent/HU230198B1/hu active Protection Beyond IP Right Term
- 2001-11-22 CN CN200910151102A patent/CN101676389A/zh active Pending
- 2001-11-22 KR KR1020097010451A patent/KR20090057335A/ko not_active Application Discontinuation
- 2001-11-22 KR KR1020037006970A patent/KR100830295B1/ko active IP Right Grant
- 2001-11-22 SI SI200130512T patent/SI1335987T2/sl unknown
- 2001-11-22 UA UA2003054618A patent/UA76731C2/uk unknown
- 2001-11-22 RU RU2003118436/13A patent/RU2290438C2/ru active
- 2001-11-22 IL IL15471201A patent/IL154712A0/xx unknown
- 2001-11-22 NZ NZ524661A patent/NZ524661A/en not_active IP Right Cessation
- 2001-11-22 DK DK01991753.3T patent/DK1335987T4/en active
-
2003
- 2003-03-03 IL IL154712A patent/IL154712A/en active IP Right Grant
- 2003-05-16 US US10/439,953 patent/US6761893B2/en not_active Expired - Lifetime
- 2003-05-16 US US10/440,073 patent/US7189536B2/en not_active Expired - Lifetime
- 2003-05-16 US US10/439,439 patent/US6913752B2/en not_active Expired - Lifetime
- 2003-05-21 NO NO20032309A patent/NO337867B1/no not_active IP Right Cessation
-
2004
- 2004-03-31 HK HK04102348.1A patent/HK1059453A1/xx not_active IP Right Cessation
-
2005
- 2005-08-05 US US11/198,557 patent/US7384644B2/en not_active Expired - Lifetime
-
2006
- 2006-03-27 CY CY20061100421T patent/CY1105594T1/el unknown
- 2006-08-23 US US11/508,797 patent/US7335364B2/en not_active Expired - Lifetime
-
2007
- 2007-10-26 US US11/977,808 patent/US7923017B2/en not_active Expired - Fee Related
- 2007-12-04 US US11/999,127 patent/US7459270B2/en not_active Expired - Lifetime
-
2009
- 2009-05-22 US US12/471,144 patent/US7939086B2/en not_active Expired - Lifetime
-
2011
- 2011-03-22 US US13/053,361 patent/US8268325B2/en not_active Expired - Lifetime
- 2011-03-22 US US13/053,450 patent/US8268329B2/en not_active Expired - Lifetime
-
2012
- 2012-08-17 US US13/588,217 patent/US20120328650A1/en not_active Abandoned
-
2013
- 2013-11-20 LU LU92311C patent/LU92311I2/fr unknown
- 2013-11-21 BE BE2013C065C patent/BE2013C065I2/fr unknown
- 2013-12-13 FR FR13C0070C patent/FR13C0070I2/fr active Active
- 2013-12-23 CY CY2013048C patent/CY2013048I2/el unknown
-
2016
- 2016-02-29 HU HUS1600010C patent/HUS1600010I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA76731C2 (uk) | Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації | |
| US7897156B2 (en) | Modified vaccinia virus ankara for the vaccination of neonates | |
| JP6130876B2 (ja) | 複製欠損性組換えウイルスワクチン中の抗原に対する細胞傷害性ｔ細胞応答に有利である反復ワクチン接種と組み合わされた最適化初期−後期プロモーター | |
| US7767209B2 (en) | Modified vaccinia virus Ankara (MVA) mutant and use thereof | |
| US8372622B2 (en) | Modified vaccinia virus ankara for the vaccination of neonates | |
| US20060127984A1 (en) | Modified Vaccinia virus Ankara for the vaccination of neonates | |
| Melamed et al. | Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants | |
| CN105101993A (zh) | 单次高剂量的mva在新生儿和婴儿中诱导保护性免疫反应 | |
| Bennett | Co-Expression of Vaccine Antigens in Vaccinia Virus |